BioAge Labs has filed a registration statement to offer and sell up to $75.0 million of its common stock in an underwritten public offering, with a 30-day option for underwriters to purchase an additional $11.25 million of shares. The shares will be sold by the company, with Goldman Sachs & Co. LLC, Piper Sandler and Citigroup acting as joint book-running managers. BioAge intends to use net proceeds, together with its existing cash, cash equivalents and marketable securities, to advance research, clinical and process development and manufacturing for its lead candidate BGE-102, support its NLRP3 and APJ programs, fund working capital and capital expenditures, reduce indebtedness and for general corporate purposes. The offering is subject to market conditions and SEC review under Form S-3 (No. 333-290688), effective November 25, 2025, and a preliminary prospectus supplement will be filed prior to closing.

BioAge has announced an indication expansion for BGE-102 into diabetic macular edema (DME), planning a randomized Phase 1b/2a proof-of-concept trial to start in mid-2026. The oral NLRP3 inhibitor has demonstrated robust reductions in inflammatory biomarkers—hsCRP, IL-6 and IL-1β—in an ongoing Phase 1 SAD/MAD trial, and preclinical models showed up to 90% preservation of retinal microvascular integrity. The DME trial will assess intraocular IL-6 reduction as its primary endpoint, with exploratory measures including best-corrected visual acuity and central subfield thickness. Results are anticipated in mid-2027, running in parallel with a cardiovascular risk Phase 2a trial expected to read out in the second half of 2026. This dual-axis strategy leverages BGE-102’s oral delivery to potentially reduce injection burden in retinal diseases while advancing its lead cardiovascular program.